Antisense Therapy (HIV-1)

Antisense Phosphorothioate Oligonucleotide GEM 91 Tested In Vitro

Published in Gene Therapy Weekly, July 14th, 1997

Multiple in vitro experiments with GEM 91, a 25-mer oligonucleotide phosphorothioate complementary to the gag initiation site of HIV-1, suggests its utility as a member of the therapeutic arsenal against HIV-1.

Koushi Yamaguchi and colleagues from the Harvard Medical School, and Hybridon, Inc., Massachusetts, collaborated on a series of in vitro experiments designed to test the therapeutic utility of GEM 91 and its resistance profile ("The Multiple Inhibitory Mechanisms of GEM 91, a gag Antisense Phosphorothioate Oligonucleotide, for Human Immunodeficiency Virus Type 1," AIDS Research and Human Retroviruses, May 1, 1997;13(7):545-54).

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1997-07-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry